Evidence map›Paper›PMID 42835020›Full record

ArticleFrontiers in oncology2026

A case report and diagnostic-therapeutic analysis of

Lijing Wang, Yang Zhou, Long Liu, Jinfeng Tian, Zhengyao Zhang, Ziyi Shao, Jingfei Shi, Shumei Liu, Chao Cui

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lijing WangDepartment of Hematology, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, China.
Yang ZhouDepartment of Hematology, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, China.
Long LiuDepartment of Hematology, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, China.
Jinfeng TianDepartment of Hematology, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, China.
Zhengyao ZhangDepartment of Hematology, The Affiliated Taian City Central Hospital of Qingdao University, Taian, Shandong, China.
Ziyi ShaoMedical School, Shandong Xiehe University, Jinan, Shandong, China.
Jingfei ShiDepartment of Clinical and Basic Medicine, Shandong First Medical University, Jinan, Shandong, China.
Shumei LiuDepartment of Hematology, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, China.
Chao CuiScientific Research Department, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma in adults, and papillary thyroid carcinoma (PTC) is the most prevalent type of thyroid malignant tumor. Chronic systemic immune dysregulation, constitutive overactivation of the PI3K/AKT/mTOR and NF-κB signaling axes, reshaped immunosuppressive tissue microenvironment and aberrant B-cell clonal expansion serve as core shared molecular and immunological mechanisms that synergistically predispose patients to synchronous tumorigenesis of papillary thyroid carcinoma and ABC-type double-expressing diffuse large B-cell lymphoma. Both are clinically high-incidence malignancies; however, cases with synchronous diagnosis of

Indexed as

case reportdiffuse large B-cell lymphomadouble primary malignant tumorsimmunochemotherapyneutropeniapapillary thyroid carcinomapolatuzumab vedotin

Identifiers

PMID42835020
PMCPMC13634846

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.